Press Release Details

YAVNE, Israel, March 23, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Prof. Lior Rosenberg, M.D., the Company's Chief Medical Technology Officer, highlighted NexoBrid^® in a presentation titled "A Novel Minimally Invasive Modality for Burn Care Based on Rapid Enzymatic Debridement" at the 2015 International Conference on Minimally Invasive Medicine (MIM 2015), held March 20-22 in Reston, Virginia.

MIM 2015 is focused on the latest research results and advanced research methods of Minimally Invasive Medicine, with attendees including clinicians and researchers from around the world.

NexoBrid is a topical pharmaceutical product that removes dead or damaged tissue, known as eschar, in a single, four-hour application without harming the surrounding healthy tissue. This minimal invasive activity reduces the need for the current standard of care of invasive and traumatic excisional surgery that involves massive tissue, blood and heat loss, and depends on highly skilled surgical personnel and surgical/blood bank facilities. Removal of eschar is the first, indispensable stage in the care of any wound, acute or chronic.

The presentation reported on a multinational, multicenter, open-label, randomized, controlled clinical trial of 156 patients age 4-55 with deep-partial and full-thickness burns, of 5-30% of their total body surface area (TBSA). The trial was conducted at major burn centers and patients were randomly assigned to burn debridement with NexoBrid or standard of care (SOC), which was non-surgical or surgical excisional debridement. Acute endpoints included incidence and area for surgical excision and autograft, and time to complete debridement. Long-term endpoints included scar quality and quality of life.

The data showed that NexoBrid significantly reduced the need (incidence) for surgery (24.5% vs. 70.0%, p &#60 0.0001), the area of burns excised (13.1% vs. 56.7%, p &#60 0.0001), the time from injury to complete debridement (2.2 days vs. 8.7 days, p &#60 0.0001) and the need for autografting (17.9% vs. 34.1%, p=0.01). In deeply burned hands, no escharotomies were done in the NexoBrid arm compared with 9.8% in the SOC arm. Scar quality, quality of life and adverse event rates were comparable in both groups.

"We are delighted to have NexoBrid's role in burn care featured at this year's MIM scientific meeting, which is focused on the vanguard of new treatments and medical technologies. The addition of a non-surgical, fast and eschar-specific debriding agent gives a new tool and treatment option to the medical teams attending to serious and severe burn victims. In clinical studies NexoBrid has demonstrated a significant reduction in the surgical burden with long-term outcomes that are comparable to the current surgical treatment. Reduction of the surgical burden and dependency on surgical personnel and facilities may also play a crucial role in mass casualty and disaster preparedness, and in military medicine," said Prof. Rosenberg.

NexoBrid has received marketing authorization from the European Medicines Agency and the Israeli Ministry of Health for the removal of eschar in adults with deep-partial and full-thickness thermal burns and has been commercially launched in Europe and Israel.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has been launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

CONTACT: Sharon Malka

         Chief Financial & Operation Officer

         MediWound Ltd.

         ir@mediwound.co.il

         

         Anne Marie Fields

         Senior Vice President

         LHA

         212-838-3777

         afields@lhai.com